MedTrace Logo

Long-Term Olanzapine Treatment in Children With Autism

NCT00183404 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-08-15

No results posted yet for this study

Summary

This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.

Conditions

Interventions

DRUG

Olanzapine

Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Drexel University

    lead OTHER

Principal Investigators

  • Richard P. Malone, MD · Drexel University College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2011-07-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00183404 on ClinicalTrials.gov